Using 68Ga-PSMA PETMRI and mpMRI to Detect Prostate Cancer in Men Aged 40 to 85 Observational Study to Compare Diagnostic Accuracy and Follow-Up Outcomes

What this Trial Is About

Researchers are investigating whether Ga-68 PSMA PETMRI can improve the diagnosis of prostate cancer compared to multiparametric MRI mpMRI in men aged 40 to 85 who have not had a prostate biopsy but show signs suspicious for prostate cancer. This observational study aims to determine if PSMA PETMRI offers better positive and negative predictive values and how lesion location agreement between PET and MRI affects diagnostic accuracy. Participants will have a Ga-68 PSMA PETMRI scan and then be monitored for two years to see if prostate cancer is diagnosed. During this period, they will visit the clinic every six months for checkups and blood tests. The study evaluates imaging results alongside clinical outcomes to assess diagnostic performance. Throughout the study, participants will undergo regular clinical assessments including blood tests every six months for two years. Researchers will measure how well the imaging techniques predict cancer presence using positive and negative predictive values based on lesion findings and PI-RADS scores. The follow-up visits and imaging aim to monitor participants health and gather data on prostate cancer diagnosis over time.

68Ga-PSMA PET/MRI in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk